spacer
home > pmps > winter 2017 > sparking innovation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Sparking Innovation

Today, human factors engineering, computational fluid dynamics, clinically relevant in vitro testing, sophisticated drug discovery and clinical trial designs are common. These and other advances offer the promise of better drugs delivered from devices that more patients can use intuitively and correctly. Such rapidly evolving methods allow international pharmaceutical companies to bring new products to market, and create openings for startup businesses. As the complexities of in vitro-in vivo correlations and bioequivalence are ironed out, the viability of systemic, nose-to-brain and sinus delivery are explored, and thermal aerosols threaten to go mainstream. It is reasonable to imagine that nasal and pulmonary drug delivery will become the portals by which biotechnology-derived products enter the body without a needle, and other drugs are delivered with unparalleled efficiency.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics receives Queen’s Award for Enterprise

Cambridge, UK, 21 April 2020: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, has be honored with a Queen’s Award for Enterprise for Innovation. The award recognizes the Company’s excellence in patenting, developing and globally commercializing single cell analysis systems for biotherapeutic discovery.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement